Table 3 Treatment and time contrast on primary outcomes

From: A randomized trial testing digital medicine support models for mild-to-moderate alcohol use disorder

Outcome

Contrast*

Estimate (95% CI)

SE

df

P

PHDD**

PS-SM

−0.205 (−0.784, 0.374)

0.242

1729

0.783

 

CI-SM

−0.145 (−0.75, 0.46)

0.253

1729

0.918

 

CI-PS

0.059 (−0.546, 0.665)

0.253

1729

0.994

 

12M-3M

−0.484 (−0.867, −0.101)

0.145

1729

0.005

 

9M-3M

−0.557 (−0.928 −0.185)

0.141

1729

<0.001

 

CI: 12M-3M

−1.149 (−1.868, −0.43)

0.273

1729

<0.001

 

CI: 9M-3M

−0.884 (−1.578, −0.189)

0.264

1729

0.005

QoL-PH

PS-SM

0.339 (−0.592, 1.269)

0.389

1728

0.767

 

CI-SM

−0.326 (−1.297, 0.644)

0.406

1728

0.806

 

CI-PS

−0.665 (−1.636, 0.306)

0.406

1728

0.275

QoL-MH

PS-SM

0.519 (−0.701, 1.739)

0.510

1728

0.670

 

CI-SM

1.540 (0.268, 2.811)

0.532

1728

0.011

 

CI-PS

1.020 (−0.252, 2.293)

0.532

1728

0.157

 

12M–3M

0.894 (0.078, 1.710)

0.310

1728

0.023

 

6M–3M

0.814 (0.165, 1.463)

0.246

1728

0.006

 

6 M: CI-SM

1.587 (0.002, 3.172)

0.663

1728

0.050

 

9 M: CI-SM

1.972 (0.277, 3.667)

0.709

1728

0.016

 

PS: 12M–3M

1.569 (0.203, 2.934)

0.518

1728

0.015

 

PS: 6M–3M

1.309 (0.214, 2.405)

0.416

1728

0.010

  1. M month, PHDD percentages of heavy drinking days, QoL-PH quality of life physical health, QoL-MH quality of life-mental health, SM self-monitoring, PS peer-supported, CI clinically integrated.
  2. *Treatment contrasts controlled for alcohol drinking severity at screening, biological sex, and outcomes at baseline. Contrasts for the main group comparisons were included. For the time and the group-by-time effects, only significant pair-wise comparisons lower than 0.05 were listed.
  3. **PHDD is a square-root transformed variable.
Back to article page